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ABSTRACT
Background
In 2003, severe acute respiratory syndrome coronavirus (SARS-CoV) was identified as the
etiological agent of severe acute respiratory syndrome, a disease characterized by severe
pneumonia that sometimes results in death. SARS-CoV is a zoonotic virus that crossed the
species barrier, most likely originating from bats or from other species including civets, raccoon
dogs, domestic cats, swine, and rodents. A SARS-CoV vaccine should confer long-term
protection, especially in vulnerable senescent populations, against both the 2003 epidemic
strains and zoonotic strains that may yet emerge from animal reservoirs. We report the
comprehensive investigation of SARS vaccine efficacy in young and senescent mice following
homologous and heterologous challenge.
Methods and Findings
Using Venezuelan equine encephalitis virus replicon particles (VRP) expressing the 2003
epidemic Urbani SARS-CoV strain spike (S) glycoprotein (VRP-S) or the nucleocapsid (N) protein
from the same strain (VRP-N), we demonstrate that VRP-S, but not VRP-N vaccines provide
complete short- and long-term protection against homologous strain challenge in young and
senescent mice. To test VRP vaccine efficacy against a heterologous SARS-CoV, we used
phylogenetic analyses, synthetic biology, and reverse genetics to construct a chimeric virus
(icGDO3-S) encoding a synthetic S glycoprotein gene of the most genetically divergent human
strain, GDO3, which clusters among the zoonotic SARS-CoV. icGD03-S replicated efficiently in
human airway epithelial cells and in the lungs of young and senescent mice, and was highly
resistant to neutralization with antisera directed against the Urbani strain. Although VRP-S
vaccines provided complete short-term protection against heterologous icGD03-S challenge in
young mice, only limited protection was seen in vaccinated senescent animals. VRP-N vaccines
not only failed to protect from homologous or heterologous challenge, but resulted in
enhanced immunopathology with eosinophilic infiltrates within the lungs of SARS-CoV–
challenged mice. VRP-N–induced pathology presented at day 4, peaked around day 7, and
persisted through day 14, and was likely mediated by cellular immune responses.
Conclusions
This study identifies gaps and challenges in vaccine design for controlling future SARS-CoV
zoonosis, especially in vulnerable elderly populations. The availability of a SARS-CoV virus
bearing heterologous S glycoproteins provides a robust challenge inoculum for evaluating
vaccine efficacy against zoonotic strains, the most likely source of future outbreaks.
The Editors’ Summary of this article follows the references.
PLoS Medicine | www.plosmedicine.org December 2006 | Volume 3 | Issue 12 | e525 2359
PLoS MEDICINEIntroduction
Severe acute respiratory syndrome coronavirus (SARS-
CoV) infection results in severe acute respiratory disease,
pneumonia, and sometimes death[1,2]. The disease was
reported in Guangdong Province, China, in 2002 and spread
to more than 30 nations within a few months. Disease severity
was linked to age and other comorbidities, with mortality
rates increasing with age and exceeding 50% in individuals
over 65 y [3]. SARS-CoV is a zoonotic virus that crossed the
species barrier, most likely originating from bats[4–6] or from
other species including civets, raccoon dogs, domestic cats,
swine, and rodents[7]. New zoonotic variants may emerge as
evidenced by sporadic cases of human disease in late 2003
and early 2004, which arose from strains distinct from that of
the epidemic [8]. In 2004, several laboratory-acquired
infections were reported, including secondary spread result-
ing in fatal disease[9]. Given the signiﬁcant health and
economic impact, the development of an effective vaccine
strategy that is protective against both epidemic and zoonotic
SARS-CoV strains is highly desirable.
Attenuated and killed SARS-CoV, DNA, and viral vectored
vaccines are being evaluated in a number of animal models
including mouse, ferret, hamster, and primate [10–23], and
have demonstrated that the SARS-CoV spike (S) glycoprotein
is the principal component of protective immunity [15,24,25].
Although strong immune responses are elicited against both S
glycoprotein and nucleocapsid (N) protein [10,15,26,27],
passive transfer studies have illustrated that only anti-S
antibody confers protection from SARS-CoV replication in
the mouse model [16,17,28]. Vaccine development faces a
series of potential concerns including reversion or recombi-
nation repair of attenuated vaccine strains, induction of
immune-mediated enhancement of pathology, waning im-
mune protection, lack of cross-protection for heterologous
strains, and limited vaccine efﬁcacy within senescent popula-
tions. Furthermore, immune enhancement has been demon-
strated with another coronavirus, feline infectious peritonitis
coronavirus [29], and more recently with a modiﬁed vaccinia
vector expressing SARS-S that exacerbated hepatitis in ferrets
while failing to protect from infection [30]. Notably, some
antibodies against the epidemic Urbani strain increased the
infectivity of lentiviruses pseudotyped with an animal SARS-S
glycoprotein in an in vitro model, raising the specter of
vaccine-mediated immune enhancement of disease following
heterotypic challenge [31]. Another potential problem is that
SARS vaccines might fail to induce antibodies that protect
from infection with divergent strains of SARS-CoV. The S
glycoprotein of SARS-CoV contains about 2%–20% amino
acid variation between zoonotic and the 2003 epidemic strains
[8,31], possibly limiting the effectiveness of monotypic SARS-S
vaccines. Finally, studies measuring the duration of protective
immunity or vaccine efﬁcacy in animals greater than 4 mo
post-boost have not yet been reported [17].
In this report, the efﬁcacy of Venezuelan equine encepha-
litis virus replicon particle (VRP) vaccines expressing the
Urbani SARS-CoV S glycoprotein (VRP-S) and N protein
(VRP-N), either individually or in combination (VRP-SþN),
are determined in young and senescent mouse models. We
tested whether the senescent mouse model, which exhibits an
age-related susceptibility to SARS-CoV similar to that seen in
the human disease [32], will provide a sensitive measure of
vaccine efﬁcacy and reveal potential complications in SARS-
CoV vaccine development for vulnerable elderly populations.
We evaluated the duration of protective immunity following
homologous and heterologous SARS virus challenge, examin-
ing the impact of waning immunity on long-term protection.
Through the use of publicly available SARS-CoV sequence
databases, bioinformatics approaches, synthetic biology, and
reverse genetics, we constructed a viable heterologous
challenge virus to test the ability of current vaccine regimens
to protect against zoonotic strains; the likely source of future
epidemics [8].
Methods
Viruses and Cells
The Urbani, Tor-2, recombinant Urbani (icSARS), and a
recombinant chimeric virus encoding the S gene of GDO3
SARS-CoV (icGD03-S), strains were propagated on VeroE6
cells in Eagle’s MEM supplemented with 10% fetal calf serum,
kanamycin (0.25 lg/ml), and gentamycin (0.05 lg/ml) at 37 8C
in a humidiﬁed CO2 incubator. For virus growth, cultures of
VeroE6 cells were infected at a multiplicity of infection (MOI)
of 1 for 1 h, the monolayer washed twice with 2 ml of PBS and
overlaid with complete MEM. Virus samples were harvested at
different times post-infection and titered by plaque assay.
Plaques were visualized by neutral red staining and then
counted.
Human nasal and tracheobronchial epithelial cells were
obtained from airway specimens rejected from patients
undergoing elective surgery under University of North
Carolina (UNC) Institutional Review Board–approved proto-
cols by the UNC Cystic Fibrosis (CF) Center Tissue Culture
Core. Brieﬂy, primary cells were expanded on plastic to
generate passage 1 cells and plated at a density of 250,000
cells per well on permeable Transwell-Col (T-Col, 12-mm
diameter; Corning [http://www.corning.com]) supports. Hu-
man airway epithelium (HAE) cultures were generated by
provision of an air–liquid interface for 4–6 wk to form well-
differentiated, polarized cultures that resemble in vivo
pseudo-stratiﬁed mucosciliary epithelium, and infected with
wild-type or recombinant SARS-CoV as previously described
by our laboratory [33]. All virus work was performed in a
biological safety cabinet (BSC cabinet) in a biosafety level
three (BSL3) laboratory containing redundant HEPA-ﬁltered
exhaust fans. Personnel were double gloved and wore Tyvek
suits with hoods supplied with HEPA-ﬁltered air by a
powered air-purifying respirator (PAPR).
Construction and Isolation of the icGDO3-CoV Variant
Virus
The GD03-S glycoprotein sequence has been reported. A
synthetic DNA containing the 59-most GD03 mutations was
purchased (Blue Heron Biotechnology [http//www.
blueheronbio.com]) and inserted into the SARS-E fragment.
The plasmid clone (SARS-E GD03) was fully sequenced and
shown to contain all of the appropriate mutations. The
remaining GDO3 mutation was incorporated by PCR muta-
genesis (59 amplicon A: 59-CTGTTTTCCCTGGGATCGC-39;
39 amplicon A: 59-NNNNNNCACCTGCTTTTGGGCAACTC-
CAATGCC-39;5 9 amplicon B: 59-NNNNNNCACCTG-
CAGTTGCCCAAAATGTTCTCTATGAGAAC-39;3 9
amplicon B: 59- CATAAATTGGATCCATTGCTGG), followed
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[34] into the SARS-F subclone. The ﬁnal construct (SARS-F
GD03) was fully sequenced and found to contain the
appropriate set of GD03-S glycoprotein alleles.
The icGDO3-S was generated as previously described.
Infectious clone fragment plasmid DNA was prepared in
Escherichia coli (TOP-10, Invitrogen [http://www.invitrogen.
com]), isolated, and puriﬁed (Qiagen [http://www.qiagen.
com]). Infectious clone fragments B, C, D, and E were
digested with BglI. Infectious clone fragments A and F were
digested with EcoRI and NotI, respectively. Infectious clone
fragments A and F were then dephosphorylated and then
digested with BglI. Individual cDNA fragments were gel
puriﬁed (Qiagen) and ligated (Roche [http://www.roche.com])
to form a full-length genomic cDNA and then chloroform
extracted and EtOH precipitated. N cDNA and full-length
viral genomic cDNA were then used as templates for in vitro
transcription reactions (Ambion [http://www.ambion.com]). N
and full-length viral genomic transcripts were then electro-
porated into Vero cells. Cell culture media containing virus
was harvested 48 h post-electroporation. Virus was plaque
puriﬁed and then passaged twice in Vero cells. The resultant
stock was plaque titered and cyropreserved at  80 8C.
Western Blot Analysis
Twelve hours post-infection, Urbani–, icSARS-CoV–, SARS-
CoV–, Tor-2–, and icGD03-S–infected cells were washed in 1X
PBS, lysed in buffer containing 20 mM Tris-HCl (pH 7.6), 150
mM NaCl, 0.5% deoxycholine, 1% Nonidet-p-40, 0.1% SDS,
and post-nuclear supernatants added to an equal volume of 5
mM EDTA/0.9% SDS, resulting in a ﬁnal SDS concentration of
0.5%. Samples were then heat inactivated for 30 min at 90 8C
in the BL3 prior to removal. At BL2, samples were again heat
inactivated for 30 min at 90 8C before use. Equivalent sample
volumes were loaded onto 4% to 20% Criterion gradient gels
(BioRad [http://www.bio-rad.com]) and then transferred to
PVDF membrane (BioRad). Blots were probed with polyclonal
mouse antisera directed against the Urbani-S glycoprotein
diluted 1:200 or convalescent human sera 1128 diluted 1:400
and developed using electrogenerated chemiluminescence
(ECL) reagents (Amersham Biosciences [http://www5.
amershambiosciences.com]). Patient #1128 was infected dur-
ing the second disease outbreak in Toronto, Canada.
Plaque Reduction Neutralization Titer Assays
One hundred plaque-forming units (pfu) of either icSARS-
CoV or icGDO3-S were treated with heat-inactivated serum
diluted to ﬁnal concentrations of 1:100, 1:200, 1:400, 1:800, or
1:1,600 and incubated at 37 8C for 30 min, and the resulting
titer determined by plaque assay. Plaque numbers formed by
virus treated with each dilution of sera from individual mice
vaccinated with VRP-S or VRP-SþN were compared to the
average number of plaques formed after treatment with a
given dilution of sera from VRP expressing the inﬂuenza A
HA protein (VRP-HA)- or PBS-vaccinated mice and ex-
pressed as the relative percentage. The dilution at which 80%
of plaques were neutralized was determined for each VRP-S–
or VRP-SþN–vaccinated animal.
Mice
Female BALB/c mice (Charles River Laboratories [http://
www.criver.com]) were anesthetized with a ketamine (1.3 mg/
mouse) and xylazine (0.38 mg/mouse) mixture administered
intraperitoneally with a 50-ll volume. Each mouse was
intranasally (i.n.) inoculated with 50 llo fv i r u sa ta
concentration of 2 3 10
6 pfu/ml of virus. Four days post-
infection, the right lung was removed and frozen at 70 8C for
later plaque assay determination of viral titers. Half of the left
lung was placed into Trizol Reagent (Invitrogen) for RNA
extraction. The second half of the left lung was ﬁxed in 4%
PFA in PBS (pH 7.4) for at least 7 d prior to parafﬁn
imbedding and sectioning for histopathological analysis. All
mice were housed under sterile conditions, and sentinel mice
were used to verify that the colony was mouse hepatitis virus
(MHV) negative. Experimental protocols were reviewed and
approved by the Institutional Animal Care and Use Commit-
tee at UNC Chapel Hill. Young mice refer to those challenged
with SARS-CoV at ages equal or less than 5 mo old, whereas
old or senescent mice are those animals with ages greater
than 1 y at the time of challenge.
Plaque Assay Titration of Virus from Lungs
Lungs were weighed and homogenized in four equivalent
volumes of PBS to generate a 20% solution. The solution was
centrifuged at 13,000 rpm on a tabletop centrifuge for 5 min,
the clariﬁed supernatant serially diluted in PBS, and 200-ll
volumes of the dilutions placed onto monolayers of Vero cells
in 60-mm dishes. Following a 1-h incubation at 37 8C, cells
were overlaid with 1% agarose-containing medium. Two days
later, plates were stained with neutral red and then plaques
counted.
VRP-S and VRP-N
The VRP constructs were made in two rounds of PCR,
the ﬁrst to generate two amplicons, and a second round of
overlapping PCR to fuse them together. The fused DNA
was digested with ApaI and AscI, and ligated into the
similarly digested pVR21 plasmid. PCR reactions were
p e r f o r m e dw i t hE x p a n dL o n gT a q( R o c h eM o l e c u l a r
Biochemicals http://www.roche-applied-science.com) in 30
cycles of 94 8C for 30 s, 55 8C for 30 s, and extensions at
68 8C for 1 min. The ﬁrst amplicon, which was used in the
construction of both VRP-S and VRP-N, was generated with
primers 59nsp4Sw (59-GATTGAGGCGGCTTTCGGCG) and
3926S (59-TTAATTAAGTCAATCGGCGCGCCCTTGGCG-
GACTAGACTATGTC) using pVR21 as template. The N-
gene–speciﬁc amplicon was produced using primers
V59SARNg (59-AGTCTAGTCCGCCAAGATGTCTGA-
TAATGGACCCCAATC) and 39SARSNg (59-NNNNTTAAT-
TAATTATGCCTGAGTTGAATCAGC) with SARS-F plasmid
for template. The S-gene–containing amplicon was made
with V59SARSg (59-AGTCTAGTCCGCCAAGATGTT-
TATTTTCTTATTATTTCTTACTCTCAC) and SARS39Sg
(59-NNNNTTAATTAATTATGTGTAATGTAATTTGA-
CACCC) using ligated SARS-E and -F fragments. The VRP-S
and VRP-N cDNA templates were sequenced for veriﬁca-
tion and replicon particles produced as previously de-
scribed [35]. Mice were vaccinated with 10
6 infectious units
(IU) of VRP in a 10-ll volume in the left rear footpad.
Lung Histopathology
Lungs were ﬁxed in 4% PFA in PBS for 7 d before being
submitted to the Histopathology Core Facility (UNC, Chapel
Hill) for parafﬁn imbedding, sectioning at 5-lm thickness,
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quarter of the total lungs were sectioned, with four to six
sections mounted from cuts taken at ﬁve different depths
within the parafﬁn-imbedded tissue. Lung pathology was
scored in a blinded manner, in which six to ten sections per
animal were evaluated and scored using the following scale.
1.0 to 2.0 ¼ no to mild inﬂammation, 2.0 to 3.0 ¼ mild to
moderate inﬂammation, 3.0 to 4.0 ¼ moderate to severe
inﬂammation in less than half of the tissue section, and 4.0 to
5.0 ¼ severe inﬂammation in more than half of the tissue
section. The same sets of tissues were also evaluated
qualitatively by a respiratory pathologist (author JH).
In Situ Hybridization
The 5 lm–thick parafﬁn-embedded sections were probed
with
35S UTP-labeled riboprobes complementary to the N
gene of SARS-CoV (Urbani) or the HA gene of the A/PR8
strain of inﬂuenza as a negative control using previously
described methods [36]. In brief, following treatment to
prevent nonspeciﬁc probe binding, the tissues were incu-
bated overnight with either probe at 5 3 10
4 cpm/lli n
hybridization buffer at 42 8C. The slides were then washed,
dehydrated, and coated with NBT emulsion (Kodak [http://
www.kodak.com]), and incubated at  80 8C. for 1 wk prior to
development. Positive signal, as determined by silver grain
deposition, was then evaluated.
Enzyme-Linked Immunosorbent Assay
Antibody titers were determined by standard indirect
enzyme-linked immunosorbent assay (ELISA). High-binding
96-well round-bottom plates (Corning [http://www.corning.
com]) were coated with 10 lg/ml of SARS-S, SARS-N, or
inactivated inﬂuenza A diluted in carbonate buffer containing
32 mM sodium carbonate, 68 mM sodium bicarbonate (pH 9.6)
at 4 8C overnight. Mouse sera, diluted 1:100 in casein blocking
buffer (Sigma [http://www.sigmaaldrich.com]), were added to
wells in duplicate, and 2-fold serial dilutions were performed,
followed by incubation for 2 h at 37 8C. Plates were then
incubated for 1 h with goat anti-mouse IgG with alkaline
phosphatase (AP) conjugate (Sigma), developed with p-nitro-
phenyl phosphate (pNPP; Sigma), and the optical density (OD)
at 405 nm was measured (Bio-Rad Model 680 microplate
reader). Log10 half-maximum ELISA titers were calculated
with Sigmaplot (Systat [http://www.systat.com]) using the
solution of the sigmoidal line of the plot of the log of the
reciprocal dilutions of mouse sera and the resulting absor-
bances to determine the log of the reciprocal dilution at which
an absorbance of 2.1 was achieved. Since very low amounts of
antibody were being measured in the passive transfer experi-
ment, log10 OD ¼ 0.2 ELISA titers were calculated.
Passive Sera Transfer
Mice were inoculated with 10
6 IU of VRP-HA, VRP-S, or
VRP-N at 7 wk of age, boosted 4 wk later, and terminally bled
via cardiac puncture 3 wk post-boost. The sera of each group
were pooled and 150 ll transferred by tail vein injection into
mice at 7 or 43 wk of age. Mice receiving sera were bled and
i.n. challenged with 10
5 pfu of icSARS.
Statistical Analysis
Unless otherwise noted, two-tailed Mann-Whitney tests
were used for statistical comparisons. The Fisher exact tests
were completed by comparing the number of animals positive
for viral replication within the lungs of a group of animals
vaccinated with VRP-S or VRP-SþN to that of the negative
control group, VRP-HA or PBS. Values outside the limit of
detection were assigned a value equal to the limit of detection
for any analysis. The plus or minus (6) symbol is used to refer
to standard deviation.
An amino acid multiple alignment was generated for the
entire S gene of viral sequences representing early, middle,
and late phases of the SARS epidemic in humans, as well as
animal strains of SARS-CoV isolated from civets and racoon
dogs found in Chinese live animal markets or housed on
farms in China that supplied the markets. The sequences were
aligned using ClustalX 1.83 with default settings [37]. A
phylogenetic tree was generated using Bayesian inference as
implemented in the program MrBayes v3.0b4 [38]. Brieﬂy, the
alignment was exported in the nexus format, the amino acid
substitution model was set to JTT [39] using the lset
command, and Markov chain Monte Carlo simulation [38]
was used to approximate the posterior probabilities of trees
with sampling conducted on four chains over 500,000
generations [40]. Trees were sampled every 100 generations,
and the 5,001 trees collected were summarized with the sumt
command set to a burnin of 1,000, which generated a
Figure 1. VRP Expression of SARS S and N and VRP-S Induction of Anti-
SARS S Antibody
(A) Western blot of cell lysates infected with VRP-S or VRP-N and probed
with human serum collected from a convalescent SARS patient, 1128.
(B–D) Western blot of lysates from cells infected with the SARS-CoV
strains Urbani, Tor2, icSARS, or icGDO3-S and probed with human
convalescent serum, 1128 (B), mouse anti–SARS-S serum from VRP-S–
vaccinated animals (C), or mouse serum from a mouse vaccinated with
VRP-N (D).
doi:10.1371/journal.pmed.0030525.g001
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value was determined using the sump command with an
arbitrary burnin of 250, which demonstrated that stationarity
occurred prior to the 100,000th generation, indicating that a
burnin of 1,000 was appropriate for the sumt command [40].
Results
Venezuelan Equine Encephalitis Virus Replicon Particles
Expressing SARS-CoV S and N
The SARS-CoV S glycoprotein gene and N protein gene
were PCR cloned, sequence veriﬁed, and inserted into
Venezuelan equine encephalitis VRPs. VRP-S and VRP-N
constructs were packaged to give titers greater than 10
9 IU
per ml and shown to express antigenically relevant recombi-
nant proteins. VRP-infected cell lysates were probed with
antiserum 1128, derived from a convalescent human SARS
patient. Western blot analysis of VRP-S–infected lysates
revealed the expected S glycoprotein doublet of approxi-
mately 180–210 kDa, whereas that of VRP-N–infected lysates
revealed a major product of less than 50 kDa, the expected
sizes for SARS-S and -N, respectively (Figure 1A). VRP-S was
inoculated into BALB/c mice and tested for its ability to
induce antigen-speciﬁc antibody. Western blots were per-
formed with Vero cell lysates infected with Urbani, SARS-
CoV Tor-2, icSARS-CoV (the Urbani recombinant virus), and
icGD03-S, a chimeric SARS-CoV expressing the S glycopro-
tein of the heterologous GDO3 strain. Blots were probed with
anti–VRP-S mouse serum, 1128 human convalescent serum,
or with anti–VRP-N mouse serum. The Western blots
demonstrated that probing with human serum resolved
bands corresponding to the major SARS antigens S (a doublet
at ;180–210 kDa) and N (triplet at ,50 kDa), as well as other
unidentiﬁed SARS-CoV proteins (Figure 1B). Serum from
mice vaccinated with VRP-S only identiﬁed SARS-S (Figure
1C), whereas serum from mice vaccinated with VRP-N
recognized SARS-N in addition to another SARS-CoV
protein that is probably a dimer of N (Figure 1D).
VRP Vaccine Efficacy against icSARS-CoV Replication in the
Mouse Model
As a general measure of vaccine efﬁcacy (Table 1, experi-
ment 1), six 4-wk-old BALB/c mice were vaccinated with
either 10
5 IU of VRP-S or VRP-HA, boosted 4 wk later with an
equal amount of VRP, and then i.n. challenged with 10
5 pfu of
icSARS-CoV 8 wk post-boost. Consistent with other studies
that made use of vectored SARS-S–expressing vaccines to
induce protective responses [16,18,41,42], vaccination with
VRP-S also prevented the replication of icSARS-CoV follow-
ing challenge. No virus was detected by plaque assay (250 pfu/
g limit of detection) in the lungs of VRP-S–vaccinated animals
at 2 d post-infection, whereas the VRP-HA–vaccinated mouse
lung had a mean titer of 6.7 6 0.5 log10 pfu/g (Figure 2A).
Vaccination with VRP-S demonstrated signiﬁcant protection
Table 1. Summary of Vaccine Groups and Select Results for Mouse Experiments
Experiment n Vaccine Age
Vaccinated
(wk)
Age
Boosted
(wk)
Challenge
Virus
Age
Challenged
(wk)
Lungs Harvested
(days Post Challenge)
Lung Titer
(log10 pfu/g)
Positive for
Viral Replication
1 6 VRP-S 4 8 icSARS 16 2 0 0/6
6 VRP-HA 4 8 icSARS 16 2 6.7 6 0.5 6/6
2 8 VRP-S 5 10 icSARS 64 4 0 0/8
8 VRP-N 5 10 icSARS 64 4 5.3 6 0.6 7/7
8 VRP-SþN 5 10 icSARS 64 4 0 0/8
7 VRP-HA 5 10 icSARS 64 4 5.8 6 0.6 8/8
3 8 VRP-S 7 10 icGDO3-S 17 2 0 0/8
8 VRP-N 7 10 icGDO3-S 17 2 6.3 6 0.1 8/8
8 VRP-SþN 7 10 icGDO3-S 17 2 0 0/8
8 VRP-HA 7 10 icGDO3-S 17 2 7.0 6 0.1 8/8
4 8 VRP-S .26 .30 icGDO3-S .62 4 5.0 6 0.9 3/8
7 VRP-N .26 .30 icGDO3-S .62 4 4.4 6 0.5 8/8
8 VRP-SþN .26 .30 icGDO3-S .62 4 3.7 6 1.2 8/8
8 PBS .26 .30 icGDO3-S .62 4 4.9 6 0.6 8/8
5 3 VRP-N 8 15 icSARS 19 2 7.5 6 0.2 3/3
3 VRP-HA 8 15 icSARS 19 2 8.1 6 0.1 3/3
3 VRP-N 8 15 icSARS 19 4 5.5 6 0.3 3/3
3 VRP-HA 8 15 icSARS 19 4 5.7 6 0.1 3/3
3 VRP-N 8 15 icSARS 19 7 0 0/3
3 VRP-HA 8 15 icSARS 19 7 3.2 6 0.5 2/3
3 VRP-N 8 15 icSARS 19 14 0 0/3
2 VRP-HA 8 15 icSARS 19 14 0 0/2
6 3 VRP-N 53 60 icSARS 64 2 8.2 6 0.2 3/3
2 VRP-HA 53 60 icSARS 64 2 8.5 6 0.1 2/2
3 VRP-N 53 60 icSARS 64 4 5.4 6 0.6 3/3
3 VRP-HA 53 60 icSARS 64 4 5.7 6 0.5 3/3
2 VRP-N 53 60 icSARS 64 7 3.7 1/2
2 VRP-HA 53 60 icSARS 64 7 3.7 6 0.5 2/2
3 VRP-N 53 60 icSARS 64 14 0 0/3
2 VRP-HA 53 60 icSARS 64 14 0 0/2
doi:10.1371/journal.pmed.0030525.t001
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control animals (p ¼ 0.007, Fisher exact test).
A second vaccine experiment was completed to evaluate
long-term VRP protection. Five-week-old BALB/c mice were
vaccinated with 10
5 IU of VRP-HA, VRP-S, VRP-N, or a
combination of VRP-S and VRP-N (VRP-SþN), and boosted 5
wk later. Fifty-four weeks post-boost, mice were i.n. chal-
lenged with 10
5 pfu of icSARS-CoV and lungs removed 4 d
post-infection (summarized in Table 1, experiment 2).
Although day 2 post-challenge demonstrates peak viral titers,
day 4 was chosen to harvest lungs because it is the time at
which the highest level of pathology is evident in senescent
mice [32]. Titers in the lungs (Figure 2B) of animals
vaccinated with VRP-S or the combination of VRP-SþN were
below the limit of detection (250 pfu/g). In contrast, the lung
titers of VRP-HA–vaccinated animals were 5.8 6 0.6 log10
pfu/g, comparable to the VRP-N–vaccinated animal titers of
5.3 6 0.6 log10 pfu/g (p¼0.2). These plaque assay results were
conﬁrmed by SARS-CoV–speciﬁc in situ hybridization on
lung tissues from the infected mice (Figure 2C). Radiolabeled
riboprobes complementary to the SARS-CoV N gene were
hybridized to sectioned lungs of ﬁve mice from VRP-HA,
VRP-N, VRP-S, or VRP-SþN vaccinated groups. Lung sections
from VRP-HA (unpublished data) and VRP-N (Figure 2C,
image a) vaccinated animals exhibited extensive in situ signal
(arrows), whereas only one of ﬁve sections from VRP-S–
vaccinated (Figure 2C, image b) and zero of ﬁve sections from
VRP-SþN–vaccinated (Figure 2C, image c) mice exhibited
SARS-CoV N-speciﬁc signal. Both VRP-S and the combina-
tion of VRP-SþN provided complete long-term protection
against challenge with the homologous vaccine strain of
SARS-CoV at 4 d post-infection (p , 0.001, Fisher exact test
for both VRP-S- and VRP-SþN–vaccinated groups relative to
VRP-HA).
Protection against Heterologous Challenge
To perform cross-protection efﬁcacy studies, it was
necessary to construct a heterologous SARS-CoV. Selection
of a likely candidate strain was made after Bayesian analysis
of the SARS-CoV S glycoprotein, which demonstrated three
main phylogenetic branches. Two of the branches include
viruses isolated from animals, such as the palm civet and
raccoon dog, and low pathogenic viruses sporadically isolated
from humans, such as GDO3 and GZ0401.Viruses represent-
ing the 2003 early, middle, and late phases of the epidemic
strains form the third branch in the SARS-S phylogenetic tree
(Figure 3A). We resurrected the S glycoprotein of GDO3, a
virus reported from a sporadic SARS case on December 22,
2003. Although GDO3 was not successfully isolated, its S
glycoprotein was sequenced and reported. Compared to
epidemic strains, GDO3 likely represented an independent
Figure 2. VRP-S Induces Short- and Long-Term Protection against icSARS-CoV Challenge
icSARS titers are expressed as the log10 plaque-forming units per gram (pfu/g) of lung. Tissues were homogenized in PBS to form a 20% suspension and
titered on Vero monolayers. The titers for individual mice are shown as a filled circle, and the mean titer for the group is represented by a solid bar. Limit
of detection (lod) is 2.4 log10 pfu/g.
(A) Lung titers of16-wk-old BALB/c mice harvested 2 d after being i.n. infected with 10
5 PFU of icSARS-CoV (n ¼ 6).
(B) Lung titers of BALB/c mice vaccinated and boosted with 10
6 infectious units (IU) of VRP expressing the influenza HA (VRP-HA), SARS-S glycoprotein
(VRP-S), SARS-N protein (VRP-N), or a combination of VRP-S and VRP-N (VRP-SþN). Mice (n¼7 VRP-HA, n¼8 for other groups) were vaccinated at 5 wk of
age, boosted 5 wk later, then i.n. challenged with 10
5 pfu of icSARS-CoV 54-wk post-boost. Lungs were harvested 4 d later and titered.
(C) Plaque assay results were confirmed by in situ hybridization to sectioned lungs of five mice from each vaccinated group with a radiolabeled
riboprobe complementary to the SARS CoV N gene. In senescent mice challenged with the icSARS-CoV, representative lung sections from VRP-HA–
(unpublished data) and VRP-N–vaccinated (a) animals exhibited extensive in situ signal (black arrows), whereas only one of five sections from VRP-S–
vaccinated (b) and zero of five sections from VRP-SþN–vaccinated (c) mice exhibited SARS-CoV–specific signal above background levels.
doi:10.1371/journal.pmed.0030525.g002
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SARS-CoV Vaccine Developmentintroduction, was reported to be less pathogenic, and its S
glycoprotein sequence is among the most divergent of all
human strains [8]. The GDO3-S glycoprotein contains 17
amino acid changes relative to Urbani-S (Figure 3B), many of
which map within neutralizing epitopes between amino acids
130–150 and 318–510, part of the receptor binding domain
(RBD) [41,43–50]. Importantly, polyclonal antibody directed
against the late-phase Urbani strain was less effective at
neutralizing pseudotyped viruses bearing GDO3-S glycopro-
teins than those bearing Urbani-S [31]. The Urbani-S
glycoprotein was removed from the SARS-CoV molecular
clone, replaced with a synthetic cDNA encoding the GD03-S
sequence, and used to generate recombinant virus [34].
Sequence analysis of plaque-puriﬁed icGDO3-S recombinant
virus conﬁrmed the presence of the GDO3-S glycoprotein
and two additional changes in the S gene relative to Urbani-S
(F7L and D613G), which likely arose as tissue-culture
adaptations. The chimeric icGDO3-S, which only differs from
Urbani SARS-CoV in its S glycoprotein, and wild-type
icSARS-CoV recombinant viruses replicated in Vero cells to
comparable titers that approached 10
7 PFU/ml within 24 h
(unpublished data) and their proteins were both detected in
Western blots with human antiserum from convalescent
patients (Figure 1B). Given the reduced amount of N present
i nt h el y s a t eo fi c G D O 3 - S – i n f e c t e dc e l l s ,t h er e d u c e d
intensity of the GDO3-S band probed with either anti–VRP-
S mouse sera or the convalescent human serum is most likely
due to the presence of lower GDO3-S protein rather than a
Figure 3. Synthetic Reconstruction of icGD03-S
(A) Unrooted phylogenetic gene tree of 35 SARS isolates ranging from early, middle, and late phases of the 2002–2003 epidemic to 2003–2004 animal
isolates. Branch confidence values are shown as posterior probabilities. The three human isolates that fall within the cluster otherwise isolated from
animals (shown in boxes), GZ0402, GD03, and GZ0401, may represent infections in which a human acquired the virus from a Himalayan palm civet.
(B) The GDO3-S glycoprotein. Amino acid changes unique to the GDO3-S with the GDO3-S amino acid listed on the left and the corresponding Urbani to
the right. The GDO3-S amino acid changes are shown in relation to the S1 and S2 subunits, the receptor binding domain (RBD), heptad repeats one
(HR1) and two (HR2), the transmembrane domain (TM), and known neutralizing epitopes. Two mutations that arose during tissue culture passage of the
chimeric icGDO3-S are shown in red.
(C) Growth curves of the Urbani strain of SARS-CoV (diamond, solid line), the recombinant Urbani icSARS (squares, dashed line), and the recombinant
chimeric virus icGDO3-S (triangles, dotted line) in human airway epithelial cells.
(D) Comparing growth of icSARS-CoV to icGDO3-S in the lungs of mice. Six-week-old female BALB/C mice were infected with icSARS-CoV or icGDO3-S (n
¼ 5 per group). The individual titer of each mouse is represented by a filled circle, and the mean titer of the group is represented as a solid bar.
doi:10.1371/journal.pmed.0030525.g003
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and Urbani-S. icGD03-S replicated efﬁciently in HAE cells,
although its maximum titer was approximately 1 log lower
than that of icSARS or Urbani (Figure 3C). To compare the
growth of icSARS and icGDO3-S in animals, 6-wk-old BALB/c
mice were i.n. infected with 10
5 pfu of either icSARS or
icGDO3-S. At 2 d post-infection, icSARS-CoV mean lung titer
was 6.8 6 0.5 log10 pfu/g, whereas icGDO3-S titers were lower
at 6.3 6 0.2 log10 pfu/g (p ¼ 0.04). The mean lung titer of
icSARS-CoV–infected mice on day 4 was 4.5 6 0.5 log10 pfu/g
compared to icGDO3-S titers of 3.7 6 0.3 (p ¼ 0.04). By the
seventh day, virus replication in the lungs of three of ﬁve
mice infected with icSARS-CoV and four of ﬁve mice infected
with icGDO3-S fell below the limit of detection (50 pfu/g).
Average icSARS-CoV and icGDO3-S titers were similar on
day 7 with 1.7 6 0.1 log10 pfu/g and 1.8 6 0.1 log10 pfu/g (p ¼
0.9), respectively (Figure 3D).
To evaluate VRP protection against short-term heterolo-
gous challenge, groups of eight animals were primed at 7 wk
of age with 10
6 IU of VRP-S, VRP-N, VRP-SþN, or VRP-HA,
boosted 3 wk later, and then challenged 7 wk post-boost with
10
5 pfu of icGD03-S (summarized in Table 1, experiment 3).
Lungs were harvested 2 d after challenge. VRP-S and VRP-
SþN protected (p , 0.001, Fisher exact test for both VRP-S
and VRP-SþN groups relative to VRP-HA) against heterolo-
gous icGD03-S recombinant virus replication (Figure 4A).
Although high titers of virus were detected in VRP-N– and
mock-vaccinated animals with mean titers of 6.3 6 0.1 and
7.0 6 0.1 log10 pfu/g, respectively, the VRP-N–vaccinated
animals had a lower mean titer (p , 0.001).
SARS-CoV vaccines should confer protection to elderly
subjects who face infection with a new variant of the virus. To
model this scenario, we vaccinated 6-mo-old to 1-y-old BALB/
c retired breeders with 10
6 IU of VRP-S, VRP-N, VRP-SþN, or
PBS, boosted them 4 wk later, and then challenged them 32
wk post-boost with 10
5 pfu of icGDO3-S (summarized in
Table 1, experiment 4). At 4 d post-infection, mean titers in
the lungs of animals vaccinated with VRP-N and PBS were
similar at 4.4 6 0.5 and 4.7 6 0.6 log10 pfu/g (p ¼ 0.2),
respectively (Figure 4B). VRP-S vaccination provided partial
protection when compared to the PBS control group (p ¼
0.026, Fisher exact test), with the lungs of three of eight
animals positive for viral replication at a mean titer of 2.9 6
1.8 log10 pfu/g. All eight of the lungs harvested from the VRP-
SþN–vaccinated animals were positive for viral replication,
although a mean titer of 3.5 6 1.2 log10 pfu/g was comparable
to the mean titer for VRP-S–vaccinated mice (p ¼ 0.4) and
reduced relative to the PBS control (p¼0.02). The presence of
SARS-CoV replication in the lungs of control and vaccinated
animals was conﬁrmed by in situ hybridization (Figure 4C).
SARS-CoV N-speciﬁc riboprobe was hybridized to lung
sections of mice from PBS-, VRP-N–, VRP-S–, and VRP-
SþN–vaccinated groups (Figure 4C). All tested lung sections
from PBS mocks (unpublished data) and VRP-N–vaccinated
(Figure 4C, image a) animals exhibited in situ signal (arrows),
although the signal did not appear to be as intense as that of
the icSARS-CoV–infected animals (Figure 2C). Lungs of the
VRP-S–vaccinated animals (Figure 4C, image b) had two of
ﬁve slides exhibiting SARS-CoV–speciﬁc signal above back-
Figure 4. VRP-S Induces Short-Term Protection against icGDO3-S in Young and Partial Protection in Old Mice
(A) Lung titers of BALB/c mice vaccinated and boosted with 10
6 IU of VRP-S, VRP-N, a combination of VRP-S plus VRP-N (VRP-SþN), or mock vaccinated
with PBS, then challenged with 10
5 pfu of icGDO3-S challenge (n ¼ 8 per group). Lungs were harvested 2 d post-challenge.
(B) Lung titers of aged BALB/c mice vaccinated at greater than 26 wk of age, boosted 4 wk later, then challenged 12 wk post-boost with icGDO3-S (n¼7
VRP-N, n ¼ 8 for other groups). Tissue was harvested 4 d post-challenge.
(C) SARS CoV specific in situ signal (black arrows) was observed in the lungs of senescent mice that were vaccinated with PBS (unpublished data) or
VRP-N (a) and challenged with icGDO3-S, although overall, the signal appeared to be less intense than that observed in the icSARS challenge animals
(Figure 2C). Vaccination with VRP-S (b) or VRP-SþN (c) failed to induce complete protection from icGD03-S challenge, as sections from two of five S- and
three of four SþN-vaccinated animals exhibited signal above that of uninfected controls.
doi:10.1371/journal.pmed.0030525.g004
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SARS-CoV Vaccine Developmentground levels, whereas VRP-SþN (Figure 4C, image c) had
three of four slides.
Senescence and VRP-S Immune Responses
Because neutralizing antibody has been reported to confer
protection from SARS-CoV replication within the lungs of
mice [13,16,28], it was of interest to determine whether the
VRP-S vaccine established high neutralizing antibody levels
that persisted until challenge. Plaque reduction neutraliza-
tion titer (PRNT) of serum samples harvested prior to
vaccination showed no neutralization of icSARS-CoV; similar
results were noted from serum collected from mice vacci-
nated with the negative controls, VRP-HA or PBS (unpub-
lished data). The 80% PRNT values (PRNT80), the dilution of
serum at which plaque numbers are reduced by 80% relative
to virus treated with control sera, for VRP-S– and VRP-SþN–
vaccinated animals at 5 and 53 wk post-boost against both
icSARS-CoV and icGDO3-S were compared (Figure 5A; Table
S1). The mean reciprocal dilutions for the PRNT80 of VRP-S
and VRP-SþN against icSARS were measured at 796 6 307 at
5 wk post-boost and 628 6 363 at 53 wk. Sera from mice
vaccinated with the combination of VRP-SþN had mean
reciprocal PRNT80 of 1,091 6 361 and 370 6 179 at 5 and 53
wk, respectively. The initial neutralizing response in animals
vaccinated with VRP-S and VRP-SþN was similar (p¼0.2 at 5
wk post-boost), and although there was not signiﬁcant waning
of the icSARS-neutralizing activity over the 48-wk period in
the VRP-S–vaccinated animals (p ¼ 0.3 Wilcoxin matched
pairs signed-rank test), VRP-SþN serum was diminished by
about 3-fold (p ¼ 0.03 Wilcoxin matched pairs signed-rank
test). All tested sera remained above the lower limit of
detection (1:100) and were sufﬁcient to prevent icSARS
replication within the lungs of challenged animals (Figure
2B). The neutralizing activity of sera from the vaccinated
animals was more effective against the vaccine strain than
against heterologous icGDO3-S virus for both sera harvests
and vaccine combinations. The reciprocal dilutions for the
PRNT80 of the VRP-S samples at 5 wk post-boost were below
the limit of detection, whereas two samples of the week 53
bleed were measured above the limit of detection with a mean
value of 112 6 28. The icGDO3-S PRNT80 measurements for
VRP-SþN at weeks 5 and 53 post-boost were below the limit
of detection with one exception for each time point: one
mouse was measured to have a PRNT80 of 124 at 5 wk, for an
average titer of 103 6 8, and another a PRNT80 of 107 at 53
wk post-boost, an average of 101 6 3.
Given that the VRP-S vaccine’s ability to provide long-term
protection was likely due to the strong SARS-CoV–neutraliz-
ing response induced in vaccinated mice, we measured the
PRNT80 of the VRP-S immune sera from mice vaccinated
when old (Table 1, experiment 4) to determine if the
incomplete protection seen in that study could be linked to
a reduced neutralizing antibody response in the senescent
animals (Figure 5B; Table S1). Against the vaccine strain, the
reciprocal dilutions of the mean PRNT80 were 170 6 82 with
two of six samples falling below the limit of detection for
VRP-S mice at 12 wk and 142 6 65 at 29 wk post-boost with
four of six falling below the limit of detection. Sera from the
VRP-SþN–inoculated mice had PRNT80 values falling near or
below the limit of detection with only one measurable sample
at 114, for an average of 103 6 6 and no icSARS-neutralizing
ability detected at week 29. Against icGDO3-S, the VRP-S
PRNT80 values were below the limit of detection with the
exception of a single VRP-S–vaccinated animal showing a
neutralizing titer of 179 at 12 wk post-boost, for an average
dilution of 116 6 35 for the group. Sera harvested from these
animals exhibited a marked reduction in neutralizing ability
when compared to the response in animals vaccinated when
young, even against the vaccine strain (p ¼ 0.008 for VRP-S
week 5 versus VPP-S week 12 post-boost; p ¼ 0.006 VRP-SþN
week 5 versus VRP-SþN week 12 post-boost). A strong anti–
SARS-CoV neutralizing response was not induced by the VRP
vaccines when administered to senescent mice.
ELISAs for total IgG speciﬁc for SARS-S and inﬂuenza-HA
were performed to compare the VRP vaccines’ ability to
induce antibody to those antigens in mice vaccinated when
young or senescent. ELISA for SARS-S was performed on sera
Figure 5. An 80% Plaque Reduction Neutralization Titers (PRNT80) for
VRP-S and VRP-SþN Hyperimmune Serum
(A) Mice vaccinated young: icSARS-CoV (left) and icGDO3-S (right) PRNT80
for VRP-S immune serum (experiment 2) collected at 5 wk post-boost (n
¼ 5) and 53 wk post-boost (n ¼ 8).
(B) Mice vaccinated old: icSARS (left) and icGDO3-S (right) PRNT80 values
for VRP-S and VRP-SþN immune serum (experiment 4) at 12 and 29 wk
post-boost (n ¼ 6 for icSARS; n ¼ 5 for icGDO3-S). The PRNT80 values for
individual animals are show as black circles, and the mean value is shown
as a solid bar. The limits of detection (1:1,600 upper and 1:100 lower) are
represented by horizontal dotted lines.
doi:10.1371/journal.pmed.0030525.g005
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vaccinated mice of experiments 2 and 4 (Figure 6A). Mice
vaccinated young with VRP-S (experiment 2) had an average
log10 half-maximum ELISA titer of 2.6 6 0.6 at 53 wk post-
boost, whereas that of the senescent animals was approx-
imately a log lower at 1.5 6 0.9 at 29 weeks post-boost (p ¼
0.007). The difference between animals of the two age groups
was even more striking when anti-S IgG levels were compared
in the VRP-SþN mice. The animals vaccinated young with
VRP-SþN had an average titer of 2.6 6 0.3, whereas the
average for senescent animals was at the limit of detection of
0.02 log10 half-maximum ELISA titer. To verify that the
reduced ability of the senescent animals to mount speciﬁc
antibody responses was not limited to the SARS-S antigen;
anti-HA IgG titers were compared in mice vaccinated with
VRP-HA. The average anti-HA titer of animals vaccinated
when young was 4.7 6 0.2, whereas the titer of the vaccinated
senescent mice was approximately one-tenth the size with a
mean titer of 3.7 6 0.8 (p , 0.001). The reduced ability of sera
harvested from senescent animals to neutralize virus corre-
lates to a general reduction in antigen-speciﬁc antibody
production.
Pathologic Findings in Mice
Lungs from the vaccinated senescent mice challenge
studies (Table 1, experiments 2 and 4) were sectioned,
hematoxylin and eosin stained, and analyzed for pathology.
Though there was some animal-to-animal variation, in
general only minor inﬂammatory changes were observed in
the senescent control mice challenged with either icSARS or
icGDO3-S (Figures 7C, 8A, and 8B). However, following
SARS-CoV challenge in senescent mice, the N-vaccinated
groups exhibited more marked bronchiolitis and alveolitis, as
well as a conspicuous perivascular and peribronchiolar
interstitial accumulation of numerous mononuclear leuko-
cytes (mainly lymphocytes and plasma cells; i.e., lymphoplas-
macytic cufﬁng) and increased numbers of widely scattered
eosinophils (Figures 7B, 7C, 8C, and 8D). Upon SARS-CoV
challenge, the animals vaccinated with SþN also exhibited a
similar, but less severe, lymphoplasmacytic inﬁltration
around pulmonary vessels and bronchiolar airways, although
alveolitis and eosinophil inﬁltration were not a prominent
feature in these animals (Figures 7F, 8G, and 8H). The lungs
of animals vaccinated with VRP-S were similar to VRP-HA–
or PBS mock-vaccinated animals with minimal lymphoplas-
macytic cell accumulations (Figures 7E, 8E, and 8F). There-
fore, not only did N vaccination fail to control SARS-CoV
replication within the lungs, but N vaccination also resulted
in an enhanced immunopathology in the lungs of the
senescent animals upon viral challenge.
Duration of N-Induced Pathology
In order to determine the kinetics of the VRP-N–associated
immunopathology and whether this effect was age depend-
ent, young and old VRP-N– or VRP-HA–vaccinated mice
were challenged with icSARS and sacriﬁced on days 2, 4, 7,
and 14 post-challenge. Young (8 wk of age) or senescent (53
wk of age) female BALB/c mice were vaccinated with 10
6 IU of
VRP-N or VRP-HA, boosted 7 wk later, then i.n. challenged
with 10
5 pfu of icSARS-CoV 4 wk post-boost. Lungs were
harvested on days 2, 4, 7, and 14, titered, and processed for
histology (Summarized in Table 1, experiments 5 and 6). In
young mice, day 2 average lung titers were 7.5 6 0.2 log10 pfu/
g and 8.1 6 0.1 log10 pfu/g for the VRP-N– and VRP-HA–
vaccinated animals, respectively. Day 4 average titers were 5.5
6 0.3 log10 pfu/g for VRP-N–vaccinated and 5.7 6 0.1 log10
pfu/g for VRP-HA–vaccinated mice. SARS titers in the VRP-
N – v a c c i n a t e dm i c el u n g sh a dd r o p p e dt ot h el i m i to f
detection by day 7, with two of the three lungs from VRP-
HA–vaccinated mice showing measurable titers at a mean of
3.2 6 0.3 log10 pfu/g. By day 14, virus was undetectable in
either group. In senescent animals, the day 2 average lung
titers were 8.2 6 0.2 and 8.5 6 0.1 log10 pfu/g for the VRP-N–
and VRP-HA–vaccinated animals, respectively. By day 4, the
mean titers had dropped to 5.4 6 0.6 log10 pfu/g for VRP-N–
vaccinated animals and 5.7 6 0.5 log10 pfu/g for the VRP-HA
controls. On day 7, one VRP-N–vaccinated mouse had a
detectable titer of 3.7 log10 pfu/g, whereas the lungs of two
Figure 6. ELISA Titers for Anti-S and Anti-HA igG in Vaccinated Animals
(A) Log10 half-maximum ELISA titers for anti-S IgG antibody in aged mice vaccinated with VRP-S or VRP-SþN when young (Table 1, experiment 2) or
senescent (Table 1, experiment 4). Values represent mean values, and error bars indicate standard deviation.
(B) Log10 half-maximum ELISA titers for anti-HA IgG antibody in aged mice vaccinated when young (experiment 2) or senescent (experiment 4).
doi:10.1371/journal.pmed.0030525.g006
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titer of 3.7 6 0.5 log10 pfu/g. No virus was detected in either
group on day 14 post–challenge.
Though enhanced inﬂammation was observed in a subset of
the VRP-N–vaccinated animals at day 2 post–infection
(Figure 9B), the inﬂammatory inﬁltrates were readily appa-
rent in both young and senescent animals at day 4 post-
infection (Figure 9D and unpublished data) and were
maintained at days 7 and 14 post-infection (Figure 9F and
9H). As had been noted previously, VRP-HA– and VRP-N–
vaccinated animals also differed by the presence of eosino-
phils (Figure 10). At day 2 post-infection, eosinophils were
rarely seen in either VRP-HA– or VRP-N–vaccinated mice
(Figure 10A and 10B, respectively). In VRP-N–vaccinated
animals, but not HA–vaccinated animals, eosinophils were
widespread on days 4 and 7 (Figure 10D and 10F), but had
largely cleared from the lungs by day 14 (Figure 10H). There
was no apparent difference in severity between the young and
senescent animals, suggesting that the immune pathology was
speciﬁc to pre-existing N immunity, but was not age
dependent (unpublished data).
Anti–SARS-N Antibody and Inflammation
A passive transfer of anti-N, anti-HA, or anti-S sera into
naive mice was performed to determine if the increased
inﬂammatory response could be attributed to N-speciﬁc
antibody, and to conﬁrm that protection in S-vaccinated
animals was mediated by S-speciﬁc antibody. Hyperimmune
sera against VRP-HA (5.26 log10 OD¼0.2 ELISA titer), VRP-N
(5.6 log10 OD¼0.2 ELISA titer), or VRP-S (5.5 OD¼0.2 ELISA
titer) were intravenously transferred in 150-ll volumes to
groups of 8-wk-old or 43-wk-old naive BALB/c mice prior to
challenge with 10
5 pfu of icSARS. Prior to challenge, serum
was collected from mice and antigen-speciﬁc IgG titered to
verify successful transfer. Young mice receiving anti–VRP-HA
(n¼4) had a mean ELISA serum titer of 2.8 6 2.4 log10 OD¼
0.2, whereas senescent mice (n¼4) had a 2.9 6 1.8 log10 OD¼
0.2 ELISA titer. The average serum titers for mice injected
with anti–VRP-N were 2.7 6 2.4 log10 OD¼0.2 ELISA titer in
young (n ¼ 4) and 2.3 6 1.9 log10 OD ¼ 0.2 ELISA titer in
senescent animals (n ¼ 4). The anti–VRP-S log10 OD ¼ 0.2
ELISA titers were 3.1 6 3.1 in young animals (n¼3) and 2.9 6
2.3 in senescent mice (n ¼ 3). Lungs were harvested 4 d post-
challenge, virus titers determined, and processed for histo-
logical analysis. Virus titers in the young mice were 5.0 6 0.1
log10 pfu/g in the anti–VRP-HA group, 5.2 6 0.1 in the anti
VRP-N group, and below the limit of detection (2.4 log10 pfu/g)
in animals injected with the anti–VRP-S. Titers in the
senescent mice were 5.3 6 0.3 log10 pfu/g in the anti–VRP-
HA group, 5.6 6 0.6 in animals receiving the anti–VRP-N, and
below the limit of detection in mice inoculated with anti–
VRP-S. None of the mice displayed the enhanced inﬂamma-
tion noted in VRP-N–vaccinated animals (unpublished data),
indicating that the observed immunopathology was not the
result of antibody-dependent enhancement.
Discussion
VRP vaccine vectors induce robust mucosal and cellular
immune responses against a large number of foreign antigens
[35,51] and were evaluated as candidate vaccines against
homologous and zoonotic SARS-CoV challenge in young and
senescent animals. Inoculation of mice with VRP-S induced
antibody that recognized the epidemic SARS-CoV S glyco-
protein as well as the S of a highly divergent strain, GDO3.
The VRP-S vaccine induced long-term protection against
challenge with the vaccine strain, complete short-term
protection against icGDO3-S challenge, and partial protec-
tion against the divergent virus in the senescent mouse
model. In contrast, vaccination with VRP-N failed to inhibit
viral replication within the lungs of either young or senescent
animals, resulted in enhanced immunopathology following
viral challenge, and did not provide any measurable beneﬁt
when combined with VRP-S. The data suggest that vaccine
regimens eliciting complete protection against antigenically
heterologous forms of SARS-CoV in healthy individuals may
not be sufﬁcient for higher risk groups, including vulnerable
Figure 7. Pathogenic Findings Following Homologous Challenge
Light photomicrographs of representative histologic lung sections (Table
1, experiment 2) taken from an untreated control mouse (A), a VRP-N–
vaccinated mouse (B) and (D), a VRP-HA–vaccinated mouse (C), a VRP-S–
vaccinated mouse (E), and a VRP-S– and VRP-N–treated mouse (F). No
histopathology was evident in (A). A marked mixed inflammatory
infiltrate composed mainly of mononuclear leukocytes (lymphocytes and
plasma cells) and widely scattered eosinophils are evident in the
perivascular and peribronchiolar interstitium (asterisk) in (B). Similar
inflammatory cells are also present in bronchiolar (br) airways and
alveolar airspaces along with enlarged and vacuolated alveolar macro-
phages (arrows). The box in (B) denotes the site of the light
photomicrograph (D) that was taken at a higher magnification to better
illustrate the lymphoplasmacytic inflammatory cell infiltrate with lesser
numbers of eosinophils (arrows). Similar, but slightly less severe,
perivascular inflammatory infiltrates (asterisk) are also present in (F),
but without accompanying alveolitis. Minimal lymphoplasmacytic cell
accumulations around the pulmonary arteriole (a) are evident in (C) and
(E). All tissues were stained with hematoxylin and eosin. Bars denote the
scale of the magnification. a, pulmonary arteriole; ap, alveolar
parenchyma; br, bronchiolar lumen; e, surface epithelium of the
bronchiole.
doi:10.1371/journal.pmed.0030525.g007
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testing of candidate vaccines that induce an anti-N response.
VRP-S vaccination generated a strong neutralizing anti-
body response (PRNT80 . 1:600) that persisted for over a year
and provided complete protection against challenge with the
vaccine strain. In humans, neutralization titers have been
measured from 1:12 to 1:512 with a geometric mean titer of
1:61 [52]. In a study evaluating an inactivated virus vaccine,
neutralizing antibody titers greater than 1:114 resulted in
complete protection against challenge [21]. Mice inoculated
with vesicular stomatitis virus vectors expressing SARS-S
developed lower average neutralizing titers of 1:32, which
were nevertheless protective against SARS-CoV infection for
up to 4 mo after vaccination [17]. We followed animals for
over 1 y after boost. To our knowledge, these are the ﬁrst
assays illustrating waning immune responses to a SARS-CoV
candidate vaccine. On average, mice vaccinated when young
with VRP-S did not show a signiﬁcant reduction in
neutralizing titers up to 53 wk post-boost, whereas mice
vaccinated with the combination of VRP-SþN experienced
about a 3-fold reduction over the same period of time.
Although it is problematic to compare our neutralizing
antibody titers to those induced by other SARS vaccines due
to the use of different assays, we demonstrate protection
from challenge with either vaccine or heterologous challenge
virus strains in animals with an icSARS PRNT80 greater than
1:114, near the assay’s limit of detection. Vaccines that induce
robust neutralizing titers against the homologous strain will
likely confer protection against zoonotic reintroductions,
especially in younger populations.
As reported with other SARS-N–expressing DNA and
vectored vaccines [15,24], VRP-N did not protect mice from
SARS-CoV replication, and no beneﬁt to vaccination with a
cocktail of both VRP-S and VRP-N was observed, although an
approximately half-log reduction in viral titers within the
lungs of some VRP-N–vaccinated mice was occasionally
observed. Although any reduction in SARS-CoV titer can be
interpreted as a positive aspect of a potential vaccine, given
the relationship between viral titer and SARS disease severity
[53,54], the increased number of lymphocytic and eosino-
philic inﬂammatory inﬁltrates, which are also characteristic
of the immune pathology observed with respiratory syncytial
virus (RSV) infection following vaccination with formalin-
inactivated RSV [55,56], raises concerns that vaccination with
N alone will not only fail to effectively protect against SARS-
CoV replication, but may result in vaccine-enhanced pulmo-
nary disease [57]. N-induced pathology has not been
previously reported, probably because most studies examined
young mice at 2–3 d post-infection, prior to the inﬁltration of
inﬂammatory cells into the lung. VRP-N–induced pathology
was clearly evident by day 4 and persisted for 1–2 wk
following wild-type virus challenge, suggesting the potential
for serious complications in lung physiology and function.
This ﬁnding has particular signiﬁcance for SARS-N and
inactivated SARS-CoV vaccines currently under development
that also induce anti-N antibody and T cell responses
[12,19,21,26,58–61], because they may lead to adverse effects.
Therefore, caution is merited with respect to the inclusion of
SARS-CoV N protein in any vaccine formulation. The passive
transfer of anti-N antibody did not contribute to inﬂamma-
tion and leads us to hypothesize that it is the activity of SARS-
N–speciﬁc T cells in the absence of effective neutralizing
anti–SARS-CoV antibody that mediates the adverse response.
It is interesting that a Th2–skewed cytokine proﬁle is a
hallmark of the RSV vaccine-enhanced disease, which raises
the possibility that the N-speciﬁc immune response is skewed
in a similar manner [62].
SARS-CoV strain diversity was mostly conﬁned to China
where many human and animal isolates were not successfully
cultured in vitro [8]. Consequently, most available exper-
imental strains, like Urbani, are nearly identical and do not
reﬂect natural diversity [63,64]. Recent advances in synthetic
biology used to reconstruct extinct viruses, or speciﬁc genes
of those viruses, de novo from their nucleotide sequences
[65–67] provide the means for expanding the number of
available SARS-CoV test strains. Using a comprehensive
SARS-CoV genetic database [8,31], we resurrected the
divergent GDO3-S glycoprotein in the Urbani genetic back-
bone. The icGD03-S recombinant virus was identical to the
molecular clone except for the presence of two mutations in
Figure 8. Pathogenic Findings Following Heterologous Challenge
Light photomicrographs of representative histologic lung sections (Table
1, experiment 4) taken from a mock PBS–vaccinated mouse (A) and (B), a
VRP-N–vaccinated mouse (C) and (D), a VRP-S–vaccinated mouse (E) and
(F), or a VRP-SþN–vaccinated mouse (G) and (H). The boxes in (A), (C), (E),
and (G) (2003 magnification) denote the site of the light photomicro-
graph that was taken at a higher magnification (4003) to better illustrate
the lymphoplasmacytic inflammatory cell infiltrates including eosinophils
(yellow arrows). All tissues were stained with hematoxylin and eosin.
doi:10.1371/journal.pmed.0030525.g008
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virus passage in Vero cells, similar to the cell culture
adaptations reported in S for other SARS-CoV strains
isolated from human clinical specimens and passaged in
vitro [68]. The icGDO3-S CoV’s sequence divergence from
Urbani, efﬁcient in vitro replication in HAE and Vero
cultures, and robust in vivo replication in the mouse model,
make it an excellent heterologous challenge inoculum for
vaccine studies. The GD03 RBD is also present in many
zoonotic isolates described in civets and raccoon dogs,
supporting its use as a zoonotic model strain [8]. Further-
more, the reduced replication in HAE cultures of icGDO3-S
compared to Urbani-CoV is consistent with the reduced
pathogenesis noted in the GDO3 human case [8,53,54].
Consistent with previous work comparing the susceptibility
of pseudotyped lentiviruses bearing the S glycoproteins of
various SARS strains to neutralization by anti-S (Urbani) IgG
[31], anti–VRP-S antibody demonstrated reduced neutraliza-
tion of icGDO3-S relative to the vaccine strain. In spite of
this, the VRP-S vaccine successfully provided short-term
protection against the divergent virus. Vaccination of
senescent animals produced signiﬁcantly reduced antibody
responses compared with younger mice, and when challenged
with the heterologous icGDO3-S virus, protection was
incomplete. However, any animal with a PRNT80 value above
1:114 against icSARS showed reduced viral replication within
the lungs following challenge with either the vaccine or
icGDO3-S strains. As noted for the homologous challenge
studies, the combination of VRP-SþN did not enhance
protection from heterologous challenge, but may actually
have weakened it, with senescent animals showing even lower
anti-S antibody responses and an even higher rate of viral
replication, albeit with reduced titers, and increased lung
pathology. One possible cause for vaccine failure is the
emergence of an escape mutant in an environment of
suboptimal neutralization. However, initial data comparing
the neutralization susceptibility of viruses isolated from these
mice to the challenge stock refute this conjecture (unpub-
lished data). Incomplete protection by a vaccine in immuno-
senescent animals and humans is well documented and is
more likely the result of an age-related compromise in one or
more stages of the immune response to the vaccine. For
instance, antibody responses in the immunosenescent tend to
offer less protection with limited switching to secondary
isotypes, lower antibody levels in general, and production of
antibody with lower afﬁnities [69–74]. Although we have not
tested single-vaccine dose regimens, previous studies have
demonstrated that these are efﬁcacious against SARS-CoV
challenge in young animals [17]. Given the low antibody titers
following boost in senescent populations, single-vaccine dose
formulations will likely prove ineffective. Rather, improving
the VRP-S efﬁcacy in older vaccinees may require additional
vaccine boosts, the use of adjuvants, or other additional
therapies [75]. Another likely contributing factor to vaccine
failure in older animals was the resistance of icGDO3-S to
neutralization relative to the vaccine strain, icSARS-CoV. At
least three neutralizing sites have been identiﬁed in the
SARS-CoV S glycoprotein, two of which map at the N-
terminus and in the RBD of the S glycoprotein, and one to a
weak third site near the carboxy-terminus of S. Given that
most of the GD03 mutations map in and around the N-
terminus and RBD in S1 [31], it is possible that either one or
both of these critical epitopes are signiﬁcantly different in
icGD03-S, and likely explains the resistance to neutralization
with antisera against Urbani-S. These data suggest that robust
neutralizing titers should be induced by candidate vaccines to
provide long-term protection from SARS-CoV infection,
especially in the vulnerable senescent population and against
heterologous strains.
Earlier work had indicated that antibodies to the Urbani
strain of SARS-CoV enhanced the in vitro infectivity of
pseudotyped viruses bearing the S glycoprotein of zoonotic
strains, primarily with strains SZ16 and SZ3, and raised the
specter of S-vaccine–induced complications with newly
emergent strains [31]. In contrast, it was shown that
monoclonal, but not polyclonal, antibodies that neutralized
the epidemic strain may enhance the infectivity of pseudo-
typed viruses bearing GD03-S glycoproteins, although the
enhanced infection was marginal at best [31]. Our research
Figure 9. Kinetics of VRP-N–Associated Inflammation
Light photomicrographs of lung sections taken from VRP-HA– and VRP-
N–vaccinated mice harvested at days 2, 4, 7, and 14 post–icSARS-CoV
challenge (Table 1, experiment 5). Representative lung sections (2003
magnification) comparing pulmonary inflammation between VRP-HA–
vaccinated (A), (C), (E), and (G) and VRP-N–vaccinated (B), (D), (F), and (H)
mice. Enhanced inflammation was evident by day 2 (A) and (B) in some
VRP-N–vaccinated animals relative to lung sections of VRP-HA–inocu-
lated mice. By day 4 post-infection (C) and (D), increased inflammation in
VRP-N–vaccinated animals was widely apparent and was maintained
through days 7 (E) and (F) and 14 (G) and (H).
doi:10.1371/journal.pmed.0030525.g009
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polyclonal antibody neutralized icGD03-S on Vero cells,
although less efﬁciently than the vaccine strain, which is
consistent with the previous report [31]. Moreover, in the
young and senescent mouse models, VRP-S–vaccinated
animals challenged with homologous or heterologous
icGD03-S recombinant viruses did not display vaccine-
mediated enhancement of virus replication or enhanced
pathology. Because VRP-S vaccines induce broad neutralizing
antibody responses that likely target multiple epitopes across
the S glycoprotein, it is possible that the noted enhancement
of infectivity with monoclonal antibodies is nulliﬁed. Indeed,
recent work showed that antibody speciﬁc for the RBD of
Tor-2–S, GDO3–S, and SZ3–S glycoproteins did not repro-
duce enhanced infectivity in pseudotyped viruses bearing
SZ3-S and identiﬁed conserved epitopes that allowed all three
strains to be effectively neutralized, raising hope that a single
vaccine could be effective against widely divergent strains of
SARS-CoV [76]. Clearly, additional studies are needed with
more heterologous strains in alternative animal models
before the possibility of vaccine-induced enhancement of
infection and pathology can be discounted.
To our knowledge, this study is the ﬁrst to demonstrate that
a SARS-CoV vaccine conferred long-term protection into the
period in which a host is most susceptible to SARS-CoV
pathology: senescence. Furthermore, the VRP-S vaccination
of young animals protected against challenge with a divergent
strain of SARS-CoV, indicating that current vaccines may also
provide protection from many zoonotic strains that might
emerge in the future. Such cross protection has been
observed among other vaccines, such as HA formulations
for inﬂuenza virus [77] and VRP vaccines against norovirus
[78]. Inducing robust immune responses in older animals is
more challenging, but VRP-S vectors provided some protec-
tion from icGDO3-S challenge, and did so without the
enhanced pathology induced by the VRP-N vaccine.
Because human infections have not been reported since
2004, animal models are essential for the development of
SARS-CoV vaccines. The young mouse model provides
readily available animals on a homogenous genetic back-
ground and efﬁcient replication within the respiratory tract.
The senescent mouse model adds the beneﬁt of enhanced
pathogenesis and mimicks the age-related susceptibility seen
in humans [32]. Although aging decreases B and T cell
immunity and innate immune function in humans and mice,
characterization of these immune deﬁciencies is incomplete
in both species. SARS-CoV infection in senescent mice
provides a key model to evaluate the mechanisms by which
aging deters immune responsiveness to highly pathogenic
emerging viruses like SARS-CoV and inﬂuenza virus, and
develop key intervention approaches to enhance vaccine
efﬁcacy in the elderly. The expense and limited availability of
other senescent species makes the mouse model invaluable.
Important caveats must be considered while evaluating this
work. Murine models of SARS disease have limitations. The
disease progression in mice is faster than in humans, rodents
and humans do not share the same symptoms, and virus
infection is less severe; limitations that are also evident in the
hamster, primate, and ferret models [79]. These shortcomings
necessitate that vaccine candidates be tested in other animal
systems and underscore the critical need for the development
of highly pathogenic challenge models for vaccine and
therapeutic testing. This report does not provide a mecha-
nism for the VRP-N–induced pathology nor provide solutions
for minimizing potential risks associated with it. Although the
passive transfer of anti–SARS-N serum did not reproduce the
inﬂammation seen in VRP-N–vaccinated animals, these
results must be interpreted with caution because the anti-N
antibody levels in the recipient mice were lower than those of
mice directly immunized by VRP-N.
The data presented in this manuscript do reveal critical
needs and potential complications in vaccine design, laying
the foundation for continuing and future studies to improve
the quality, safety, and efﬁcacy of SARS-CoV vaccines. Our
model systems provide a means for identifying the host
factors that contribute to immune senescence and will allow
us to evaluate whether changes in vaccine design or regimen
Figure 10. Identifying Eosinophils among Inflammatory Infiltrates
The 4003magnification comparing eosinophil infiltration within the lung
sections of VRP-HA–vaccinated (A), (C), (E), and (G) and VRP-N–vaccinated
(B), (D), (F), and (H) mice (Table 1, Experiment 5). At day 2 post-infection
(A) and (B), eosinophils are rarely evident in the lungs of either VRP-HA
(A) or VRP-N (B) mice. Day 4 post-infection (C) and (D), extensive
eosinophils (yellow arrows) are present within the lungs of VRP-N–
vaccinated mice. Widespread eosinophils are seen at day 7 post-
challenge in VRP-N–vaccinated (F), but not VRP-HA–vaccinated (E) mice.
By day 14 (G) and (H), eosinophils are rarely found among inflammatory
cells of VRP-N–vaccinated mice. An identical experiment in old animals
was performed simultaneously (Table 1, experiment 6), showed results
indistinguishable from those of young mice (unpublished data). All
tissues were stained with hematoxylin and eosin.
doi:10.1371/journal.pmed.0030525.g010
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models provide clear rational to test candidate SARS vaccines
in the hamster, ferret, and primate models in which
pathology and clinical disease are more prominent following
wild-type virus challenge. Our research provides a model for
future experiments designed to characterize the components
and inducers of the VRP-N–enhanced pulmonary inﬂamma-
tion, and suggests that vaccine regimens that contain N
protein should be used with caution in human populations
until further testing. The successful resurrection of a novel
recombinant SARS challenge virus bearing zoonotic S
glycoproteins suggests that it might be feasible to reconstruct
other rare zoonotic SARS-CoVs that have never been
successfully cultured, providing novel challenge viruses for
vaccine and therapeutic drug testing against potential future
zoonotic SARS introductions into human populations.
Finally, these studies should encourage the development of
senescent animal models of human disease and encourage
vaccine testing and design against inﬂuenza, West Nile virus,
and other pathogens that produce disproportionate disease
burdens in the elderly [80,81].
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Background. Severe acute respiratory syndrome (SARS) is a flu-like
illness and was first recognized in China in 2002, after which the disease
rapidly spread around the world. SARS was associated with high death
rates, much higher than those for flu. Around 10% of people recognized
as being infected with SARS died, and the death rate approached 50%
among elderly people. The virus causing SARS was identified as a
member of the coronavirus family; it is generally thought that this virus
‘‘jumped’’ to humans from bats, which harbor related viruses. Although
SARS was declared eradicated by the World Health Organization in May
2005, there is still the possibility that similar viruses will again cross the
species barrier and infect humans, with potentially serious consequen-
ces. As a result, many groups are working to develop vaccines that will
protect against SARS infection.
Why Was This Study Done? A SARS vaccine should be effective in
people of all ages, including the elderly who are more likely to get
seriously ill or die if they become infected. In addition, potential vaccines
should protect against different variants of the virus, because there are
different types of the virus that could potentially cross the species barrier
from animals to humans. Of the different proteins that make up the SARS
coronavirus, the spike glycoprotein is thought to elicit an immune
response in humans that can protect against future infection. The
researchers therefore examined vaccine candidates based on this
particular protein (termed SARS-CoV S), as well as a second one called
SARS-CoV N, in mice. Specifically, they tested whether the vaccines
would protect against SARS infection in both young and older mice, and
whether they would protect against infection by different strains of the
SARS virus.
What Did the Researchers Do and Find? The researchers created
vaccines based on SARS-CoV S and SARS-CoV N by taking the genes
coding for those proteins and inserting them into another type of virus
particle that acted as a delivery vehicle. They injected mice with these
vaccines and then tested whether the mice generated an immune
response against the specific SARS proteins, which they did. The next
step was to work out whether mice injected with the vaccines would be
protected against later infection with SARS-CoV. The researchers found
that mice injected with vaccine based on SARS-CoV S were protected
against later infection with a standard SARS-CoV strain, both in the short
term (eight weeks after vaccination) and the long term (54 weeks after
vaccination). However, the vaccine based on SARS-CoV N did not seem
to result in protection, and, worryingly, caused pathological changes in
the lungs of mice following virus challenge. To find out if their candidate
vaccines would protect against different strains of SARS, the researchers
made a synthetic test virus that contained a mixture of genetic material
from different natural variants of the virus. This test virus was used to
‘‘challenge’’ mice that had been immunized with the two different
vaccines. The researchers found that the vaccine based on SARS-CoV S
protected against infection by the test virus when mice were vaccinated
young, but it failed to efficiently protect when administered to older
mice.
What Do These Findings Mean? The findings confirm others
suggesting that vaccines based on the SARS-CoV S protein are more
effective than those based on SARS-CoV N. They also suggest that the
former can provide long-term protection in animals vaccinated young
against closely related viruses. However, protection against more
distantly related viruses remains a challenge, especially when vaccinating
older animals. The differences seen between young and older mice
suggest that older mice might provide a useful model for animal testing
of candidate vaccines for diseases like SARS, flu, and West Nile virus that
pose a particular threat to elderly people. Overall, these results provide
useful lessons toward future SARS vaccine development in animals. The
synthetic virus strain generated here, and others like it, are likely to be
useful tools for such future studies.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030525.
  The World Health Organization provides guidance, archives, and other
information resources on SARS
  Information from the US Centers for Disease Control on SARS
  Wikipedia (an internet encyclopedia anyone can edit) has an entry on
SARS
  Collected resources from MedLinePlus about SARS
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